Literature DB >> 19453997

Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes.

George Sgourakis1, Arnold Radtke, Ioannis Fouzas, Sofia Mylona, Kostantinos Goumas, Ines Gockel, Hauke Lang, Constantine Karaliotas.   

Abstract

To examine the impact of steroid withdrawal from the immunosuppression protocols in liver transplantation. The electronic databases Medline, Embase, Pubmed and the Cochrane Library were searched. Meta-analysis pooled the effects of outcomes of a total of 2590 patients enrolled into 21 randomized controlled trials (RCTs), using classic and modern meta-analytic methods. Meta-analysis of RCTs addressing patients transplanted for any indication showed no differences between corticosteroid-free immunosuppression and steroid-based protocols in most of the analyzed outcomes. More importantly, steroid-free cohorts appeared to benefit in terms of de novo diabetes mellitus development [R.R = 1.86 (1.43, 2.41)], Cytomegalovirus (CMV) infection [R.R = 1.47 (0.99, 2.17)], cholesterol levels [WMD = 19.71 (13.7, 25.7)], the number of patients that received the allocated treatment [O.R = 1.55 (1.17, 2.05)], severe acute rejection [R.R = 1.71 (1.14, 2.54)] and overall acute rejection [R.R = 1.31 (1.09, 1.58)] (when steroids were replaced in the steroid-free arm). Taking RCTs into account independently when steroids were not replaced, overall acute rejection was favoring the steroid-based arm [R.R = 0.75 (0.58, 0.98)]. Studies addressing exclusively transplanted HCV patients demonstrated a significant advantage of steroid-free protocols considering HCV recurrence [R.R = 1.15 (1.01, 1.13)], acute graft hepatitis [O.R = 3.15 (1.18, 8.40)], and treatment failure [O.R = 1.87 (1.33, 2.63)]. No unfavorable effects were observed after steroid withdrawal during short-term follow-up. On the contrary, significant advantages were documented.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453997     DOI: 10.1111/j.1432-2277.2009.00893.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  23 in total

Review 1.  Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review.

Authors:  George Sgourakis; Georgia Dedemadi
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial.

Authors:  Khurram Bari; Shimul A Shah; Tiffany E Kaiser; Robert M Cohen; Nadeem Anwar; David Kleesattel; Kenneth E Sherman
Journal:  Liver Transpl       Date:  2020-08-19       Impact factor: 5.799

Review 3.  Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence.

Authors:  Shirin Elizabeth Khorsandi; Nigel Heaton
Journal:  Transl Gastroenterol Hepatol       Date:  2016-04-06

4.  Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience.

Authors:  Vicky L Ng; Estella M Alonso; John C Bucuvalas; Geoff Cohen; Christine A Limbers; James W Varni; George Mazariegos; John Magee; Susan V McDiarmid; Ravinder Anand
Journal:  J Pediatr       Date:  2011-12-20       Impact factor: 4.406

Review 5.  Management of recurrent hepatitis C virus after liver transplantation.

Authors:  Miguel Jiménez-Pérez; Rocío González-Grande; Francisco Javier Rando-Muñoz
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

6.  A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years.

Authors:  Shawn J Pelletier; Satish N Nadig; David D Lee; John B Ammori; Michael J Englesbe; Randall S Sung; John C Magee; Robert J Fontana; Jeffrey D Punch
Journal:  HPB (Oxford)       Date:  2012-09-28       Impact factor: 3.647

Review 7.  Irreversible liver failure: treatment by transplantation: part 3 of a series on liver cirrhosis.

Authors:  Andreas Pascher; Maxim Nebrig; Peter Neuhaus
Journal:  Dtsch Arztebl Int       Date:  2013-03-08       Impact factor: 5.594

Review 8.  Current strategies for immunosuppression following liver transplantation.

Authors:  Daniel Nils Gotthardt; Helge Bruns; Karl Heinz Weiss; Peter Schemmer
Journal:  Langenbecks Arch Surg       Date:  2014-04-20       Impact factor: 3.445

Review 9.  Liver transplantation for malignancy: current treatment strategies and future perspectives.

Authors:  Christina Hackl; Hans J Schlitt; Gabriele I Kirchner; Birgit Knoppke; Martin Loss
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 10.  Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.

Authors:  Luit Penninga; André Wettergren; Colin H Wilson; An-Wen Chan; Daniel A Steinbrüchel; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2014-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.